Google's smart contact lens granted patent

Google has been granted a patent by the U.S. patent office for its smart contact lens featuring a chip, electric circuit and sensor technology, according to multiple reports.

The search giant has previously said it is partnering with the pharmaceutical company Novartis to create a smart contact lens that could monitor blood sugar for people with diabetes. Google has been testing various prototypes of smart contact lens and is currently in talks with the FDA about a lens that measures glucose levels in users’ tears, according to an article in TIME. The company says the chip and sensor are embedded between two layers of contact lens material and a tiny pinhole lets tear fluid from the eye reach the glucose sensor, which can measure levels every second.

A patent report published at the time stated it was one of Google's many applications relating to "systems and/or methods for capturing image data representing a scene in a gaze of a viewer via a thin image capture component integrated on or within a contact lens, processing the image data, and employing the processed image data to perform functions locally on the contact lens or remotely on one or more remote devices."

The camera component can track and generate data of an image of a scene corresponding to the gaze of the wearer without obstructing the wearer's view, the report said.

Google had announced it was working on a contact lens for measuring and monitoring glucose at the start of 2014 with plans to make the contact lens available to consumers in 2019.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.